Mepolizumab for eosinophilic chronic rhinosinusitis, loss of smell and challenges with accessibility to allergen immunotherapy. Shamji MH, Boyle RJ. Clin Exp Allergy 2022;52:1358-1360.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Shamji MH, Boyle RJ. Mepolizumab for eosinophilic chronic rhinosinusitis, loss of smell and challenges with accessibility to allergen immunotherapy. Clin Exp Allergy 2022;52:1358-1360.
PMID: 36509425